PwPepwise

MGF (Mechano Growth Factor)

Muscle & Performance

a.k.a. IGF-1Ec

IGF-1 splice variant

Mechano Growth Factor (MGF) is a splice variant of insulin-like growth factor-1 (IGF-1).

§01Summary

Mechano Growth Factor (MGF) is a splice variant of insulin-like growth factor-1 (IGF-1) that the body produces naturally in response to mechanical stress, exercise, or muscle injury. Unlike the liver-derived form of IGF-1 that circulates in the bloodstream, MGF acts locally at the site of damaged or overloaded muscle tissue, where it appears to play a key early role in activating the satellite (stem) cells responsible for muscle repair and growth17,19. Research in human skeletal muscle shows that resistance exercise may significantly increase MGF expression, and the degree of upregulation appears to correlate with the magnitude of subsequent muscle fiber growth3. Endogenous MGF levels are significantly lower in elderly individuals with sarcopenia compared to those with normal muscle mass, suggesting it contributes to the maintenance of skeletal muscle throughout life6. Notably, MGF expression appears blunted in aging muscle following mechanical loading, which may help explain the reduced capacity for muscle adaptation seen in older adults12. The combination of resistance training and growth hormone administration may produce the greatest increases in MGF expression, suggesting synergistic regulation by both mechanical and hormonal signals1. As a therapeutic peptide, MGF is being investigated for its potential in muscle repair, age-related muscle loss, and regenerative medicine, with the evidence base actively developing.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

MGF (Mechano Growth Factor), formally designated IGF-IEc in humans, arises from alternative splicing of the IGF-1 gene following mechanical loading, stretch, or tissue damage. The defining molecular feature of MGF is a 49–52 base pair insert in the E domain of the IGF-1 pre-mRNA, which causes a reading frame shift that produces a unique C-terminal E peptide sequence distinguishing MGF from the liver-derived systemic isoform IGF-IEa14. This structural divergence has functional consequences: the MGF E domain peptide appears to signal through a receptor distinct from the canonical IGF-1 receptor (IGF1R), as demonstrated by antibody blocking experiments in myoblast cultures16, though the identity of this alternative receptor remains an area of active investigation.

At the cellular level, the MGF E domain promotes myoblast proliferation while simultaneously inhibiting terminal differentiation — a combination that serves to expand the progenitor cell pool available for subsequent differentiation into mature myofibers16. This is mechanistically distinct from mature IGF-1, which primarily promotes differentiation and protein synthesis. Endogenous MGF is expressed earliest among the IGF-1 isoforms following muscle damage, preceding both IGF-IEa and satellite cell activation marker M-cadherin17,19. This temporal precedence positions MGF as an initiating signal in the regenerative cascade, with IGF-IEa subsequently upregulated to drive the anabolic protein synthesis phase of repair17.

MGF production requires intact mechanotransduction machinery: expression is absent in dystrophic muscle models lacking either dystrophin or laminin, even under mechanical stimulation, implicating the dystrophin-associated cytoskeletal complex as a required upstream component of MGF mechanosensing14. Mechanical strain, rather than contractile activity or metabolic load per se, appears to be the primary trigger — electrical stimulation alone without stretch produces no significant upregulation of MGF mRNA in animal models18. Regulatory inputs are not purely mechanical; growth hormone synergizes with resistance training to produce MGF upregulation substantially exceeding that of either stimulus alone, suggesting shared upstream transcriptional regulators of the IGF-1 gene prior to isoform-specific alternative splicing1.

Bidirectional regulatory interactions exist between MGF/IGF isoforms and the myogenic regulatory factors (MRFs) Myf5, MyoD, myogenin, and Mrf4, with IGFs inducing MRF expression and MRFs potentially regulating IGF expression in return2. Age-related blunting of the MGF response to mechanical loading — observed in both elderly men and older females12,20 — suggests progressive impairment of mechanotransduction upstream of IGF-1 gene splicing rather than a deficit in baseline expression, with resting MGF levels remaining comparable between young and old subjects despite divergent exercise responses12.

§04Evidence & efficacy

Evidence base
317Studies
100Human
60Animal

In human skeletal muscle, endogenous MGF mRNA upregulation following resistance exercise may serve as a meaningful biomarker of hypertrophic potential. In a resistance training cohort, extreme hypertrophic responders showed a 126% increase in MGF transcript levels 24 hours after the initial training bout, compared to 73% in modest responders and no significant change in non-responders, with fiber cross-sectional area gains averaging 2,475 µm² in the top responder cluster3. Resistance training alone may increase MGF mRNA by approximately 163% over five weeks, and the combination of resistance training with growth hormone administration may produce increases as large as 456%1. In elderly populations, MGF levels are independently and significantly associated with appendicular skeletal muscle mass index, suggesting a role in maintaining muscle mass during aging6. However, MGF expression appears attenuated in older compared to younger skeletal muscle following identical mechanical loading12, and the MGF response to resistance loading in young males may reach 91% while remaining non-significant in other age-sex subgroups20.

At the cellular level, the MGF E domain peptide appears to promote myoblast proliferation while inhibiting terminal differentiation — effects mediated through a receptor pathway distinct from the classical IGF-1 receptor16. MGF expression precedes satellite cell activation markers following muscle damage17,19, consistent with a role as an early initiator of the muscle regeneration cascade.

All human efficacy data pertains to endogenous MGF expression; human efficacy data for exogenous MGF peptide administration is emerging through ongoing preclinical and early translational research.

§05Safety

The available peer-reviewed literature does not include any clinical trials or formal safety studies evaluating exogenous MGF peptide administration in humans. All human research identified involves measurement of endogenous MGF mRNA or protein levels in response to exercise or hormonal stimulation1,3,6,12,20, or in vitro characterization of MGF E domain peptide effects on myoblast cultures16. No adverse event data, tolerability data, or pharmacovigilance information from human MGF peptide administration is present in the reviewed studies.

From a mechanistic standpoint, the MGF E domain appears to signal through a receptor distinct from the classical IGF-1 receptor16, which means that safety assumptions cannot be directly borrowed from the established IGF-1 clinical literature. The temporal and tissue-specific nature of endogenous MGF expression — rapid, transient, and locally confined to mechanically loaded or damaged muscle17,19 — suggests the endogenous molecule operates within tightly regulated biological constraints, though how sustained or systemic exogenous administration would interact with those constraints is being studied in preclinical models.

Human safety data for exogenous MGF peptide therapy is an active area of clinical investigation.

§06History

MGF as a distinct molecular entity was identified in the late 1990s through the work of Geoffrey Goldspink and colleagues, who cloned a mechanically responsive splice variant of the IGF-1 gene from overloaded skeletal and cardiac muscle and named it Mechano Growth Factor to reflect its induction by mechanical stimuli14. The foundational 1999 paper established that MGF contains a unique E domain insert causing a reading frame shift, localizes to mechanically stressed tissue rather than circulating systemically, and is absent in dystrophic muscle models — distinguishing it structurally and functionally from liver-derived IGF-114. Early animal studies in the late 1990s and early 2000s characterized the stretch-dependent expression kinetics of MGF in rabbit skeletal muscle18 and its temporal relationship to satellite cell activation following muscle damage in rodent models17,19.

The first direct human evidence emerged in 2002, when Hameed and colleagues demonstrated that resistance exercise upregulated MGF mRNA in young but not elderly subjects, linking the isoform to age-related muscle decline12. A key mechanistic milestone came the same year when Yang and Goldspink demonstrated that the MGF E domain peptide acts through a receptor distinct from IGF1R to promote myoblast proliferation while inhibiting differentiation16. The first human RCT examining MGF regulation was published in 2003, characterizing synergistic upregulation by combined growth hormone and resistance training in elderly men1. Subsequent human studies established MGF transcript levels as a differential biomarker of hypertrophic responsiveness3 and confirmed its independent association with skeletal muscle mass in sarcopenic populations6. The translational development of exogenous MGF peptide therapeutics represents the current frontier, with preclinical and early human research actively progressing.

§07References